Xilio, Ventyx IPOs raise $269M to fuel plans to compete with big pharma drugs

Healthcare

Cancer drug developer Xilio Therapeutics and Ventyx Biosciences, a company with drug candidates in cancer and autoimmune diseases, are the latest life science companies to go public. They’ll use proceeds from their respective IPOs to continue clinical development of drugs being positioned as competitors to drugs from big pharmaceutical companies.

Leave a Reply